Early drug development predictions of glass-forming ability and physical stability of drugs

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 2, 2013, Pages 323-332

  Mahlin, Denny ^a   Bergström, Christel A S ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Amorphous stability; Crystallization temperature; Glass transition temperature; Glass forming ability; Molecular weight; Prediction

Indexed keywords

ACEMETACIN; ACETOHEXAMIDE; ALBENDAZOLE; BEZAFIBRATE; BICALUTAMIDE; BUCETIN; BUFEXAMAC; CAFFEINE; CARBAMAZEPINE; CHLORZOXAZONE; DIFLUNISAL; FAMOTIDINE; FELODIPINE; GLAFENINE; GLIBENCLAMIDE; GRISEOFULVIN; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; HYDROFLUMETHIAZIDE; INDOMETACIN; LACTOSE; LINAPRAZAN; METOLAZONE; NIFEDIPINE; OMEPRAZOLE; PIMOZIDE; SPIRONOLACTONE; TESTOSTERONE; UNINDEXED DRUG; WARFARIN;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; GLASS TRANSITION TEMPERATURE; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; POWDER DIFFRACTION; PRIORITY JOURNAL; SOLID STATE; SPRAY DRYING; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; DRUG COMPOUNDING; DRUG STABILITY; GLASS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; POWDER DIFFRACTION; TRANSITION TEMPERATURE; X-RAY DIFFRACTION;

EID: 84877037504     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.03.016     Document Type: Article

References (37)

1. Y. Aso, S. Yoshioka, and S. Kojima Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by C-13 nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature Journal of Pharmaceutical Sciences 90 2001 798 806
2. J.A. Baird, B. Van Eerdenbrugh, and L.S. Taylor A classification system to assess the crystallization tendency of organic molecules from undercooled melts Journal of Pharmaceutical Sciences 99 2010 3787 3806
3. S. Bhattacharya, and R. Suryanarayanan Local mobility in amorphous pharmaceuticals-characterization and implications on stability Journal of Pharmaceutical Sciences 98 2009 2935 2953
4. C. Bhugra, and M.J. Pikal Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state Journal of Pharmaceutical Sciences 97 2008 1329 1349
5. C. Bhugra, R. Shmeis, S.L. Krill, and M.J. Pikal Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times Journal of Pharmaceutical Sciences 97 2008 455 472
6. S. Branchu, P.G. Roqueda, A.P. Plumb, and W.G. Cook A decision-support tool for the formulation of orally active, poorly soluble compounds European Journal of Pharmaceutical Sciences 32 2007 128 139
7. V. Caron, C. Bhugra, and M.J. Pikal Prediction of onset of crystallization in amorphous pharmaceutical systems: phenobarbital, nifedipine/PVP, and phenobarbital/PVP Journal of Pharmaceutical Sciences 99 2010 3887 3900
8. D.O. Corrigan, O.I. Corrigan, and A.M. Healy Predicting the physical state of spray dried composites: salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems International Journal of Pharmaceutics 273 2004 171 182
9. K.A. Graeser, J.E. Patterson, J.A. Zeitler, K.C. Gordon, and T. Rades Correlating thermodynamic and kinetic parameters with amorphous stability European Journal of Pharmaceutical Sciences 37 2009 492 498
10. B.C. Hancock, and M. Parks What is the true solubility advantage for amorphous pharmaceuticals? Pharmaceutical Research 17 2000 397 404
11. B.C. Hancock, and G. Zograf Characteristics and significance of the amorphous state in pharmaceutical systems Journal of Pharmaceutical Sciences 86 1997 1 12
12. B.C. Hancock, S.L. Shamblin, and G. Zografi Molecular mobility of amorphous pharmaceutical solids below their glass-transition temperatures Pharmaceutical Research 12 1995 799 806
13. W. Kauzmann The nature of the glassy state and the behavior of liquids at low temperatures Chemical Reviews 43 1948 219 256
14. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications International Journal of Pharmaceutics 420 2011 1 10
15. K.L. Kearns, S.F. Swallen, M.D. Ediger, T. Wu, Y. Sun, and L. Yu Hiking down the energy landscape: progress toward the Kauzmann temperature via vapor deposition Journal of Physical Chemistry B 112 2008 4934 4942
16. Laitinen, R.; Löbmann, K.; Strachan, C.J.; Grohganz, H.; Rades, T.; 2012. Emerging trends in the stabilization of amorphous drugs. International Journal of Pharmaceutics, in press.
17. Y. Lin, R.P. Cogdill, and P.L.D. Wildfong Informatic calibration of a materials properties database for predictive assessment of mechanically activated disordering potential for small molecule organic solids Journal of Pharmaceutical Sciences 98 2009 2696 2708
18. L. Lindfors, S. Forssen, P. Skantze, U. Skantze, A. Zackrisson, and U. Olsson Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations Langmuir 22 2006 911 916
19. D. Mahlin, S. Ponnambalam, M. Heidarian Höckerfelt, and C.A.S. Bergström Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development Molecular Pharmaceutics 8 2011 498 506
20. P.J. Marsac, H. Konno, and L.S. Taylor A comparison of the physical stability of amorphous felodipine and nifedipine systems Pharmaceutical Research 23 2006 2306 2316
21. S.B. Murdande, M.J. Pikal, R.M. Shanker, and R.H. Bogner Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals Pharmaceutical Research 27 2010 2704 2714
22. W. Ping, D. Paraska, R. Baker, P. Harrowell, and C.A. Angell Molecular engineering of the glass transition: glass-forming ability across a homologous series of cyclic stilbenes The Journal of Physical Chemistry B 115 2011 4696 4702
23. Å. Schoug, D. Mahlin, M. Jonson, and S. Håkansson Differential effects of polymers PVP90 and Ficoll400 on storage stability and viability of Lactobacillus coryniformis Si3 freeze-dried in sucrose Journal of Applied Microbiology 99 2009 2032 2048
24. S. Singh, and J.J. de Pablo A molecular view of vapor deposited glasses The Journal of Chemical Physics 134 2011 194903 194907
25. E.B. Stukalin, J.F. Douglas, and K.F. Freed Application of the entropy theory of glass formation to poly(alpha-olefins) Journal of Chemical Physics 131 2009 114905
26. R. Surana, A. Pyne, and R. Suryanarayanan Effect of preparation method on physical properties of amorphous trehalose Pharmaceutical Research 21 2004 1167 1176
27. C.V. Thompson, and F. Spaepen On the approximation of the free energy change on crystallization Acta Metallurgica 27 1979 1855 1859
28. N.S. Trasi, S.X.M. Boerrigter, and S.R. Byrn Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin Pharmaceutical Research 27 2010 1377 1389
29. D. Turnbull Under what conditions can a glass be formed? Contemporary Physics 10 1969 473 488
30. B. Van Eerdenbrugh, J.A. Baird, and L.S. Taylor Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation-classification and comparison with crystallization tendency from undercooled melts Journal of Pharmaceutical Sciences 99 2010 3826 3838
31. S. Vyazovkin, and I. Dranca Effect of physical aging on nucleation of amorphous indomethacin Journal of Physical Chemistry B 111 2007 7283 7287
32. T. Wu, and L. Yu Surface crystallization of indomethacin below Tg Pharmaceutical Research V23 2006 2350 2355
33. T.X. Xiang, and B.D. Anderson Molecular dynamics simulation of amorphous indomethacin Molecular Pharmaceutics 10 2013 102 114
34. T. Yamaguchi, M. Nishimura, R. Okamoto, T. Takeuchi, and K. Yamamoto Glass-formation of 4′′-O-(4-methoxyphenyl)acetyltylosin and physicochemical stability of the amorphous solid International Journal of Pharmaceutics 85 1992 87 96
35. F. Zhang, J. Aaltonen, F. Tian, D.J. Saville, and T. Rades Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin European Journal of Pharmaceutics and Biopharmaceutics 71 2009 64 70
36. D. Zhou, G.G.Z. Zhang, D. Law, D.J.W. Grant, and E.A. Schmitt Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility Journal of Pharmaceutical Sciences 91 2002 1863 1872
37. S. Ziffels, and H. Steckel Influence of amorphous content on compaction behaviour of anhydrous [alpha]-lactose International Journal of Pharmaceutics 387 2010 71 78